These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 18164899)
41. Adverse reactions to short-acting nifedipine in hypertensive crises. Spizzirri F; Rahman R Pediatr Nephrol; 1999 May; 13(4):366. PubMed ID: 10454793 [No Abstract] [Full Text] [Related]
42. Evaluation of the safety of short-acting nifedipine in children with hypertension. Egger DW; Deming DD; Hamada N; Perkin RM; Sahney S Pediatr Nephrol; 2002 Jan; 17(1):35-40. PubMed ID: 11793132 [TBL] [Abstract][Full Text] [Related]
43. Calcium channel antagonists: morbidity and mortality--what's the evidence? Straka RJ; Swanson AL; Parra D Am Fam Physician; 1998 Apr; 57(7):1551-60. PubMed ID: 9556644 [TBL] [Abstract][Full Text] [Related]
44. Child with small bowel obstruction and perforation secondary to ileal bezoar. Quintana JF; Walker RN; McGeehan A Pediatr Emerg Care; 2008 Feb; 24(2):99-101. PubMed ID: 18277846 [TBL] [Abstract][Full Text] [Related]
45. Nifedipine in ischemic heart disease. Kloner RA Circulation; 1995 Sep; 92(5):1074-8. PubMed ID: 7648647 [No Abstract] [Full Text] [Related]
46. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Saito I; Saruta T; Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866 [TBL] [Abstract][Full Text] [Related]
47. [Efficacy of antihypertensive drugs in pregnancy]. Tsaava F; Shonia R Georgian Med News; 2005 Sep; (126):23-6. PubMed ID: 16234587 [TBL] [Abstract][Full Text] [Related]
49. Evidence for the risk of calcium channel blockers in hypertension was selective. Hanna FW; Peters JR; Rees JA BMJ; 1996 Nov; 313(7067):1259-60. PubMed ID: 8939129 [No Abstract] [Full Text] [Related]
50. [Severe obstructive ileus caused by a linseed bezoar. Case report with critical comment on the use of dietary fiber]. Hardt M; Geisthövel W Med Klin (Munich); 1986 Jul; 81(15-16):541-3. PubMed ID: 3023805 [No Abstract] [Full Text] [Related]
51. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737 [TBL] [Abstract][Full Text] [Related]
52. Dihydropyridine calcium channel blockers and peripheral side effects. Sirker A; Missouris CG; MacGregor GA J Hum Hypertens; 2001 Oct; 15(10):745-6. PubMed ID: 11607807 [No Abstract] [Full Text] [Related]
53. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. Ellis JS; Seymour RA; Steele JG; Robertson P; Butler TJ; Thomason JM J Periodontol; 1999 Jan; 70(1):63-7. PubMed ID: 10052772 [TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study. Fujikawa K; Hasebe N; Kikuchi K; Hypertens Res; 2005 Jul; 28(7):585-91. PubMed ID: 16335887 [TBL] [Abstract][Full Text] [Related]
55. [The hemodynamic effects of lomir and adalat in patients with postoperative arterial hypertension]. Eremenko AA; Ziuliaeva TP; Bozh'eva LV; Borisov RIu Anesteziol Reanimatol; 1999; (5):63-6. PubMed ID: 10560156 [TBL] [Abstract][Full Text] [Related]
56. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Hermida RC; Ayala DE; Mojón A; Fernández JR Am J Hypertens; 2008 Aug; 21(8):948-54. PubMed ID: 18600215 [TBL] [Abstract][Full Text] [Related]
57. Bezoar formed by fragments of extended-release nifedipine tablets. Shepherd MF Clin Pharm; 1993 Nov; 12(11):849-52. PubMed ID: 8275650 [No Abstract] [Full Text] [Related]
58. Calcium channel blockers for the management of preterm birth: a review. Nassar AH; Aoun J; Usta IM Am J Perinatol; 2011 Jan; 28(1):57-66. PubMed ID: 20640972 [TBL] [Abstract][Full Text] [Related]
59. The FDA's decisions regarding new indications for approved drugs. Where's the evidence? Winker MA JAMA; 1996 Oct 23-30; 276(16):1342-3. PubMed ID: 8861995 [No Abstract] [Full Text] [Related]
60. [The efficacy of antihypertension drugs and their combinations in the non-treated hypertension]. Ruksin VV; Grishin OV; Chiritso MM Med Tr Prom Ekol; 2013; (5):7-11. PubMed ID: 24000722 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]